In the last decade the inhibition of the enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11β-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11β-HSD1 (IC50=0.7 μM).
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ivf1NM
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Excerpt from Common Culture: Reading and Writing About American Popular Culture. Ed. Michael Petracca, Madeleine Sorapure. Upper Saddle Rive...
-
Thesis Statement Creator: Directions: This web page explains the different parts to a thesis statement and helps you create your own. You ca...
-
Robert Schumann regnes som en av de store romantiske komponistene, særlig anerkjent er hans klaver- og kammermusikk. Han startet på utdanni...
-
Effect of titanium oxide and zirconium oxide nanoparticle incorporation on the flexural strength of heat-activated polymethyl methacrylate d...
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Related Articles Return of Genetic Research Results to Participants and Families: IRB Perspectives and Roles. J Law Med Ethics. 2015;...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου